Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 9/2013

01-09-2013 | Thoracic Oncology

REG1A Expression Status Suggests Chemosensitivity Among Advanced Thoracic Esophageal Squamous Cell Carcinoma Patients Treated with Esophagectomy Followed by Adjuvant Chemotherapy

Authors: Yusuke Sato, MD, PhD, Satoru Motoyama, MD, PhD, Hiroshi Nanjo, MD, PhD, Satoru Ito, Kei Yoshino, MD, PhD, Tomohiko Sasaki, MD, PhD, Kuniaki Kuribayashi, MD, Yushi Nagaki, MD, Kazuhiro Imai, MD, PhD, Hajime Saito, MD, PhD, Yoshihiro Minamiya, MD, PhD, Jun-ichi Ogawa, MD, PhD

Published in: Annals of Surgical Oncology | Issue 9/2013

Login to get access

Abstract

Background

Regenerating gene 1A (REG1A) plays an important role in tissue regeneration and in cell proliferation in the mucous membrane of the gastrointestinal tract. We previously reported that the positive expression status of REG1A was predictive of chemoradiosensitivity in patients treated with preoperative chemoradiotherapy before esophagectomy or with definitive chemoradiotherapy. To further confirm the utility of REG1A as a chemosensitivity marker, we carried out an additional retrospective clinical study aimed at determining whether REG1A is a reliable chemosensitivity marker in patients treated with esophagectomy followed by adjuvant chemotherapy.

Method

A total of 177 patients with T2–4 thoracic esophageal squamous cell carcinoma received curative surgery without preoperative treatment at Akita University Hospital between 2001 and 2011. A tissue microarray was constructed, and REG1A expression status was analyzed immunohistochemically. We then statistically analyzed the relationships between REG1A expression status and 5-year overall survival (OS), disease-specific survival (DSS), and disease-free survival (DFS).

Results

In the adjuvant group (n = 105), REG1A-positive patients showed significantly better prognoses than REG1A-negative patients. (5-year OS, p = .0022; DSS, p = .0004; and DFS, p = .0040). However, there were no significant differences between REG1A-positive and REG1A-negative patients in the surgery group (n = 72). Univariate and multivariate analyses showed REG1A expression status to be a significant prognostic factor affecting 5-year DSS, comparable to lymph node metastatic status.

Conclusion

The present study suggests REG1A expression status has the potential to be a highly reliable and clinically useful chemosensitivity marker in patients treated with advanced thoracic esophageal squamous cell carcinoma. REG1A expression status will provide a good indication of treatment strategy and enable more individualized treatment for patients.
Literature
1.
Ando N, Ozawa S, Kitagawa Y, Shinozawa Y, Kitajima M. Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg. 2002;232:225–32.CrossRef
2.
Law S, Kwong D, Wong KF, Wong KH, Chu KM, Sham JS, et al. Improvement in treatment results and long-term survival of patients with esophageal cancer: Impact of chemoradiation and change in treatment strategy. Ann Surg. 2003;238:339–47.PubMed
3.
Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study—JCOG9204. J Clin Oncol. 2003;21:4592–6.PubMedCrossRef
4.
Kato K, Muro K, Minashi K, Ohtsu A, Ishikura S, Boku N, et al. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II–III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys. 2011;81:684–90.PubMedCrossRef
5.
Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68–74.PubMedCrossRef
6.
Sanuki N, Ishikura S, Shinoda M, Ito Y, Hayakawa K, Ando N. Radiotherapy quality assurance review for a multi-center randomized trial of locally advanced esophageal cancer: the Japan Clinical Oncology Group (JCOG) trial 0303. Int J Clin Oncol. 2012;17:105–11.PubMedCrossRef
7.
Terazono K, Yamamoto H, Takasawa S, Shiga K, Yonemura Y, Tochino Y, et al. A novel gene activated in regenerating islets. J Biol Chem. 1988;263:2111–4.PubMed
8.
Watanabe T, Yonekura H, Terazono K, Yamamoto H, Okamoto H. Complete nucleotide sequence of human reg gene and its expression in normal and tumoral tissues. The reg protein, pancreatic stone protein, and pancreatic thread protein are one and the same product of the gene. J Biol Chem. 1990;265:7432–9.PubMed
9.
Miyaoka Y, Kadowaki Y, Ishihara S, Ose T, Fukuhara H, Kazumori H, et al. Transgenic overexpression of Reg protein caused gastric cell proliferation and differentiation along parietal cell and chief cell lineages. Oncogene. 2004;23:3572–9.PubMedCrossRef
10.
Unno M, Itoh T, Watanabe T, Miyashita H, Moriizumi S, Teraoka H, et al. Islet beta-cell regeneration and reg genes. Adv Exp Med Biol. 1992;321:61–9.PubMedCrossRef
11.
Sekikawa A, Fukui H, Fujii S, Ichikawa K, Tomita S, Imura J, et al. REG Ialpha protein mediates an anti-apoptotic effect of STAT3 signaling in gastric cancer cells. Carcinogenesis. 2008;29:76–83.PubMedCrossRef
12.
Yoshino N, Ishihara S, Rumi MA, Ortega-Cava CF, Yuki T, Kazumori H, et al. Interleukin-8 regulates expression of Reg protein in Helicobacter pylori-infected gastric mucosa. Am J Gastroenterol. 2005;100:2157–66.PubMedCrossRef
13.
Astrosini C, Roeefzaad C, Dai YY, Dieckgraefe BK, Jöns T, Kemmner W. REG1A expression is a prognostic marker in colorectal cancer and associated with peritoneal carcinomatosis. Int J Cancer. 2008;123:409–13.PubMedCrossRef
14.
Lee WS, Seo G, Shin HJ, Yun SH, Yun H, Choi N, et al. Identification of differentially expressed genes in microsatellite stable HNPCC and sporadic colon cancer. J Surg Res. 2008;144:29–35.PubMedCrossRef
15.
Kimura N, Yonekura H, Okamoto H, Nagura H. Expression of human regenerating gene mRNA and its product in normal and neoplastic human pancreas. Cancer. 1992;70:1857–63.PubMedCrossRef
16.
Cavard C, Terris B, Grimber G, Christa L, Audard V, Radenen-Bussiere B, et al. Overexpression of regenerating islet-derived 1 alpha and 3 alpha genes in human primary liver tumors with beta-catenin mutations. Oncogene. 2006;25:599–608.PubMedCrossRef
17.
Minamiya Y, Kawai H, Saito H, Ito M, Hosono Y, Motoyama S, et al. REG1A expression is an independent factor predictive of poor prognosis in patients with non-small cell lung cancer. Lung Cancer. 2008;60:98–104.PubMedCrossRef
18.
Sasaki Y, Minamiya Y, Takahashi N, Nakagawa T, Katayose Y, Ito A, et al. REG1A expression is an independent factor predictive of poor prognosis in patients with breast cancer. Ann Surg Oncol. 2008;15:3244–51.PubMedCrossRef
19.
Geng J, Fan J, Wang P, Fang ZJ, Xia GW, Jiang HW, et al. REG1A predicts recurrence in stage Ta/T1 bladder cancer. Eur J Surg Oncol. 2009;35:852–7.PubMedCrossRef
20.
Motoyama S, Sugiyama T, Ueno Y, Okamoto H, Takasawa S, Nanjo H, et al. REG I expression predicts long-term survival among locally advanced thoracic squamous cell esophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by esophagectomy. Ann Surg Oncol. 2006;13:1724–31.PubMedCrossRef
21.
Hayashi K, Motoyama S, Sugiyama T, Izumi J, Anbai A, Nanjo H, et al. REG Ialpha is a reliable marker of chemoradiosensitivity in squamous cell esophageal cancer patients. Ann Surg Oncol. 2008;15:1224–31.PubMedCrossRef
22.
Hayashi K, Motoyama S, Koyota S, Koizumi Y, Wang J, Takasawa S, et al. REG I enhances chemo- and radiosensitivity in squamous cell esophageal cancer cells. Cancer Sci. 2008;99:2491–5.PubMedCrossRef
23.
Sato Y, Motoyama S, Maruyama K, Yoshino K, Sasaki T, Wakita A, et al. CMV reactivation caused by methylprednisolone therapy for ARDS after esophagectomy. Esophagus. 2012;9:141–6.CrossRef
24.
Motoyama S, Saito R, Kitamura M, Ogawa J. Outcome of active surgery during intensive follow-up for second primary malignancy after esophagectomy for thoracic squamous cell esophageal carcinoma. J Am Coll Surg. 2003;197:914–20.PubMedCrossRef
25.
Sato Y, Motoyama S, Maruyama K, Okuyama M, Ogawa J, et al. A second malignancy is the major cause of death among thoracic squamous cell esophageal cancer patients negative for lymph node involvement. J Am Coll Surg. 2005;201:188–93.PubMedCrossRef
26.
Camp RL, Neumeister V, Rimm DL. A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J Clin Oncol. 2008;26:5630–7.PubMedCrossRef
27.
Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest. 2000;80:1943–9.PubMedCrossRef
28.
Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Köchli OR, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol. 2001;159:2249–56.PubMedCrossRef
29.
Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31:1869–83.PubMedCrossRef
30.
Miyata H, Doki Y, Shinozaki H, Inoue M, Yano M, Fujiwara Y, et al. CDC25B and p53 are independently implicated in radiation sensitivity for human esophageal cancers. Clin Cancer Res. 2000;6:4859–65.PubMed
31.
Takasawa S, Ikeda T, Akiyama T, Nata K, Nakagawa K, Shervani NJ, et al. CyclinD1 activation through ATF-2 in Reg-induced pancreatic b-cell regeneration. FEBS Lett. 2006;580:585–91.PubMedCrossRef
Metadata
Title
REG1A Expression Status Suggests Chemosensitivity Among Advanced Thoracic Esophageal Squamous Cell Carcinoma Patients Treated with Esophagectomy Followed by Adjuvant Chemotherapy
Authors
Yusuke Sato, MD, PhD
Satoru Motoyama, MD, PhD
Hiroshi Nanjo, MD, PhD
Satoru Ito
Kei Yoshino, MD, PhD
Tomohiko Sasaki, MD, PhD
Kuniaki Kuribayashi, MD
Yushi Nagaki, MD
Kazuhiro Imai, MD, PhD
Hajime Saito, MD, PhD
Yoshihiro Minamiya, MD, PhD
Jun-ichi Ogawa, MD, PhD
Publication date
01-09-2013
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 9/2013
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-013-2983-9

Other articles of this Issue 9/2013

Annals of Surgical Oncology 9/2013 Go to the issue

Hepatobiliary Tumors

Long-Term Outcomes Comparing Surgery to Embolization-Ablation for Treatment of Solitary HCC <7 cm

Endocrine Tumors

Multicenter Institutional Experience of Surgically Resected Thymic Epithelial Tumors (TETs): An Observational Report on Behalf of F.O.N.I.C.A.P. (Forza Operativa Nazionale Interdisciplinare Contro il Cancro del Polmone)

Gastrointestinal Oncology

D2 Lymphadenectomy with Surgical Ex Vivo Dissection into Node Stations for Gastric Adenocarcinoma Can Be Performed Safely in Western Patients and Ensures Optimal Staging

Breast Oncology

A Model to Predict the Risk of Upgrade to Malignancy at Surgery in Atypical Breast Lesions Discovered on Percutaneous Biopsy Specimens

Urologic Oncology

Gleason 5+4 Has Worse Oncological and Pathological Outcomes Compared with Gleason 4+5: Significance of Gleason 5 Pattern

Thoracic Oncology

Nodal Skip Metastasis is not a Predictor of Survival in Thoracic Esophageal Squamous Cell Carcinoma